All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Yi-Bin Chen is the Director of the Hematopoietic Cell Transplant and Cell Therapy Program and holds the Allen B. Rogers, Jr. and Cara J. Rogers Endowed Chair at Massachusetts General Hospital, Boston, US. In addition, he is an Associate Professor of Medicine at Harvard Medical School, Boston, US.
Chen earned his BS/MS in molecular biophysics and biochemistry from Yale University, New Haven, US, followed by obtaining his medical degree from Harvard Medical School. He completed his internship and residency at Massachusetts General Hospital, where he also served as chief medical resident. He then completed a fellowship in hematology and oncology at the Dana-Farber Brigham Cancer Center, Boston, US, combined program.
Chen’s research focuses on improving the outcomes of patients undergoing bone marrow transplantation (BMT). He has served as an investigator or principal investigator for many clinical trials involving numerous aspects of BMT, including conditioning regimens, alternative graft sources, novel treatments and prophylactic approaches for acute and chronic graft-versus-host disease, and the use of maintenance therapies after BMT.